Why the study?
Does mavacamten monotherapy improve left ventricular outflow tract gradients and symptoms in patients with obstructive hypertrophic cardiomyopathy?
Population
Patients with obstructive hypertrophic cardiomyopathy across four phase 3 studies
Comparison
Mavacamten monotherapy vs mavacamten plus beta-blockers or calcium-channel blockers
Design
Integrated analysis of four phase 3 studies
Follow-up
Week 128
Key result
Mavacamten monotherapy improved left ventricular outflow tract gradients and symptoms in obstructive hypertrophic cardiomyopathy, with LVEF reductions of ≤8.8% at 128 weeks.
Authors
Loading...
Mavacamten monotherapy may improve LVOT gradients and symptoms in obstructive HCM; leaves open comparative efficacy versus combination regimens.
Meta-Analysis
Does mavacamten monotherapy improve left ventricular outflow tract gradients and symptoms in patients with obstructive hypertrophic cardiomyopathy?
Mavacamten monotherapy appears effective and safe for obstructive hypertrophic cardiomyopathy, showing similar efficacy and safety trends to combination therapy with beta-blockers or calcium-channel blockers.
Olivotto et al. (2026) conducted a meta-analysis in obstructive hypertrophic cardiomyopathy. Mavacamten monotherapy vs. Mavacamten plus beta-blockers or calcium-channel blockers was evaluated on left ventricular outflow tract gradients and symptoms. Mavacamten monotherapy improved left ventricular outflow tract gradients and symptoms in obstructive hypertrophic cardiomyopathy, with LVEF reductions of ≤8.8% at 128 weeks.